CN106397417A - Preparation method for preparing posaconazole midbody - Google Patents

Preparation method for preparing posaconazole midbody Download PDF

Info

Publication number
CN106397417A
CN106397417A CN201610771038.8A CN201610771038A CN106397417A CN 106397417 A CN106397417 A CN 106397417A CN 201610771038 A CN201610771038 A CN 201610771038A CN 106397417 A CN106397417 A CN 106397417A
Authority
CN
China
Prior art keywords
compound
reaction
dichloromethane
dried
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610771038.8A
Other languages
Chinese (zh)
Inventor
魏鹏飞
王宁
冯伟伟
王仕祥
朱映普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GANSU HAOTIAN CHEMEXPRESS CO Ltd
Original Assignee
GANSU HAOTIAN CHEMEXPRESS CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GANSU HAOTIAN CHEMEXPRESS CO Ltd filed Critical GANSU HAOTIAN CHEMEXPRESS CO Ltd
Priority to CN201610771038.8A priority Critical patent/CN106397417A/en
Publication of CN106397417A publication Critical patent/CN106397417A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a method for preparing a posaconazole midbody shown as the formula 1. According to the preparation method, a compound 2 reported in literature is used as a raw material; firstly, trialkyl silane is used for protecting hydroxyl to obtain a compound 3; then, the compound 3 takes a reaction with sodium salts 4 of triazole to obtain a compound 5; next, siloxane removal is performed under the effects of paratoluensulfonyl chloride and alkali, and toluenesulfonyl protection is performed to obtain a compound 1. The method provided by the invention can overcome the defects in the prior art; a splicing step is not performed; the occurrence of side reaction and the appearance of impurities are reduced; the reaction selectivity and the yield are improved. The formulas are shown as the accompanying drawing.

Description

For preparing the preparation method of the intermediate of posaconazole
Technical field
The present invention relates to a kind of preparation method of organic compound, it is Specifically that its structure is as shown in Equation 1 can use Preparation method in the compound 1 preparing antifungal agent posaconazole (Posaconazo le) intermediate.
Background technology
Posaconazole (Posaconazo le), the antifungal developed for celestial spirit-Schering-Plough (Schering-Plough) New drug.Be mainly used in those because after bone marrow transplantation immunity weaken with numeration of leukocyte reduce patient, to prevent some mycetes The infection causing with yeast-like fungi.The body of these patients is difficult to resist above-mentioned infection after accepting cancer chemotherapy.U.S. FDA In September in 2006 approval on the 18th.
The English language Chemical title of posaconazole is:4-[4-[4-[4-[[(3R,5R)-5-(2,4-Difluorophenyl)- 5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl] phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one;Chinese chemical name:4- [4- [4- [4- [[(3R, 5R) -5- (2,4 difluorobenzene base) -5- (1,2,4- triazol-1-yl methyl) oxa- penta ring -3- base] methoxy Base] phenyl] piperazine -1- base] phenyl] -2- [the amyl- 3- yl of (2S, 3S) -2- hydroxyl] -1,2,4- triazole -3- ketone;Molecular formula: C37H42F2N8O4;Relative molecular weight:700.78;CAS registration number:171228-49-2.Posaconazole since the advent of the world, domestic There is outward a lot of patents and document report its preparation method.
Patent WO2013042138A2 reports following route synthesising target compound:But the presence of hydroxyl leads to three When nitrogen azoles connects, it is susceptible to intramolecular nucleophilic channel (hydroxyl replacement iodine), yield is low, and impurity is obvious.
US5403937A reports following route and has synthesized target compound:The same with above-mentioned route, hydroxyl leads to Reaction selectivity is poor, and inner molecular reaction can react generation impurity between disturbing molecule, reduces yield.
WO9517407A1, US5661151A, WO9638443A1 report following synthetic route:This route synthesis condition Complexity, and building-up process will be through splitting, and the yield of resolution reaction is less than 40%, and combined coefficient is extremely low.
Content of the invention
For the problem overcoming above-mentioned route to exist, the present invention provides a kind of preparation being greatly improved compound 1 to receive The preparation method of rate.
The preparation method is that with document it has been reported that compound 2 be raw material, protected with trialkyl silyl first Hydroxyl obtains compound 3, then reacts with the sodium salt 4 of triazole again, obtains compound 5, then in paratoluensulfonyl chloride and alkali In the presence of desiliconization ether carry out p-toluenesulfonyl protection and obtain compound 1, the trialkyl silyl in preparation method of the present invention, I.e. R can be trimethyl silicane or triethyl group silicon or t-Butyldimethylsilyl, and alkali used is potassium carbonate or sodium carbonate Or sodium bicarbonate or triethylamine or pyridine or imidazoles.
Avoid in preparation process of the present invention that (intramolecular nucleophilic takes with the disturbing reaction of hydroxyl during triazole coupling reaction Generation reaction), without splitting step, occur with decreasing side reaction generation and impurity, improve selectivity and the yield of reaction.
Specific embodiment
It is in DMF or dichloromethane that compound 2 is dissolved in DMF, is then added thereto to suitably Alkali, and trialkyl silicon chloride RX.Obtain compound 3 after the completion of reaction, directly its DMF solution is carried out next step or enter Row be quenched, extract, being dried, concentrate post processing after be re-dissolved in DMF carrying out next step reaction.
Above-mentioned gained compound 3 is dissolved in DMF, in reactant liquor, then adds 3-5 times of mole Triazole sodium salt compound 4 and the DMPU of 1-1.5 mole, are heated to 80-140 DEG C and stir 24 hours, after the completion of reaction, add water Reaction is quenched, with dichloromethane extraction, gained organic faciess are the solution of compound 5, can by silica gel column chromatography purification or Purified with such a way:With saturated common salt water washing organic faciess, then use salt acid extraction, gained aqueous hydrochloric acid solution is water-soluble with KOH Liquid or NaOH aqueous solution or sodium bicarbonate aqueous solution or aqueous sodium carbonate tune PH=8-9, are then extracted with ethyl acetate Take, then be dried, concentrate after obtain yellow oil, then with ethyl acetate and normal hexane crystallization obtain faint yellow solid 5.
The compound 5 obtaining is added in dichloromethane, adds 1-1.5 to be rubbed by the triethylamine of mole and 0.01-0.1 The DMAP of your amount, is then dividedly in some parts the paratoluensulfonyl chloride of 1-1.5 mole, reaction is stirred at room temperature at 0 DEG C After the completion of, through extraction, acid-alkali washing, drying, filter, be evaporated after obtain yellow oil, purified with silica gel column chromatography or Obtain the high white solid of purity 1 with isopropanol and petroleum ether crystallization.
Embodiment one:
1mmol compound 2 is dissolved in DMF, is then added thereto to 1.1mmol potassium carbonate, stirs Mix down that to be slowly added dropwise thereto into 1.2mmol trim,ethylchlorosilane be TMSCl.After 1h, that is, obtain the solution of 3a, then to reaction In liquid, addition 4mmol triazole sodium salt compound 4 and 1.2mmol 1,3- dimethyl -3,4,5,6- tetrahydrochysene -2 (1H) pyrimidone are DMPU, is heated to 100-110 DEG C and stirs 24 hours, TLC shows and completes.Add water (1.5L), is extracted with dichloromethane (50ml*2), Dichloromethane saturated aqueous common salt (20mL) washed once, then is extracted with 15%HCl (40ml*2), aqueous hydrochloric acid solution dichloromethane Alkane (40ml*2) washs, and aqueous hydrochloric acid solution adjusts PH=8-9 with 50%NaOH (about 100mL), is extracted with ethyl acetate (70ml*2), Saturated aqueous common salt (500ml*2) washs, Na2SO4It is dried, concentrates, obtain yellow oil, add ethyl acetate (100ml), stir Mix 10min), it is dividedly in some parts normal hexane (common 20ml), 0 DEG C of stirring 2h, sucking filtration, obtain faint yellow solid 5a, yield 56.6% is pure Degree 90%.
Take 0.8mmol 5a to be added in dichloromethane, add 1mmol pyridine, 0.1mmol DMAP is DMAP.0 DEG C is dividedly in some parts 1mmol paratoluensulfonyl chloride is TsCl, is stirred at room temperature 1 day, reaction completes.Reactant liquor is poured into In 1mol/L aqueous hydrochloric acid solution (20ml), add dichloromethane (20ml), point liquid, organic faciess are washed with 1mol/L hydrochloric acid (20ml) Wash, then use saturation Na2CO3(500ml*2) wash, Na2SO4It is dried, filter, be spin-dried for, obtain yellow oil, plus isopropanol (5ml), stir 5min, be dividedly in some parts petroleum ether (30ml), stir 2 hours, filter, petroleum ether (20ml) washs, and dries and obtains White solid 1, with isopropanol 30ml in 60 DEG C of recrystallization, obtain the high white solid of purity 1, yield 48%, purity 98.5%.
Embodiment two:
3mmol compound 2 is dissolved in dichloromethane 20mL, is then added thereto to 3.3mmol imidazoles, under stirring to Wherein being slowly added dropwise into 3.6mmol chlorotriethyl silane is TESCl.After 1h, add water quenching to go out in reactant liquor, then divide liquid, All organic faciess are concentrated to dryness after being dried and obtain 3b.
2mmol 3b is dissolved in 10mLDMF, adds 10mmol triazole sodium salt compound 4 He in reactant liquor 2mmol1,3- dimethyl -3,4,5,6- tetrahydrochysene -2 (1H) pyrimidones are DMPU, are heated to 100-110 DEG C and stir 24 hours.Add water (1.5L) it is quenched, is extracted with dichloromethane (50ml*2), dichloromethane saturated aqueous common salt (20mL) washed once, Na2SO4 It is dried, concentrate, obtain yellow oil, silica gel column chromatography purification obtains faint yellow solid 5b, yield 46%, purity 96%.
Take 0.8mmol 5a to be added in dichloromethane, add 1mmol triethylamine, 0.05mmol DMAP. 0 DEG C is dividedly in some parts 1mmol paratoluensulfonyl chloride, is stirred at room temperature 1 day, reaction completes.Reactant liquor is poured into 1mol/L hydrochloric acid water-soluble In liquid (20ml), add dichloromethane (20ml), point liquid, organic faciess are washed with 1mol/L hydrochloric acid (20ml), then use saturation Na2CO3 (500ml*2) wash, Na2SO4It is dried, filters, be spin-dried for, obtain yellow oil, silica gel column chromatography purification obtains high white of purity Color solid 1, yield 54%, purity 98.0%
Embodiment three:
3mmol compound 2 is dissolved in DMF, is then added thereto to 3.3mmol pyridine, stirring Under to be slowly added dropwise thereto into 3.6mmol tert-butyl chloro-silicane be TBDMSCl.After 1h, add water quenching in reactant liquor Go out, then divide liquid, all organic faciess are concentrated to dryness after being dried and obtain 3b.
2mmol 3b is dissolved in 10mLDMF, adds 10mmol triazole sodium salt compound 4 and 2mmol in reactant liquor DMPU, is heated to 100-110 DEG C and stirs 24 hours.Add water (1.5L) be quenched, with dichloromethane (50ml*2) extraction, dichloromethane Mutually be washed once with saturated aqueous common salt (20mL), Na2SO4It is dried, concentrate, obtain yellow oil, silica gel column chromatography purification obtains Faint yellow solid 5b, yield 51%, purity 96%.
Take 0.8mmol 5a to be added in dichloromethane, add 1mmol potassium carbonate, 0.03mmol DMAP. 0 DEG C is dividedly in some parts 1mmol paratoluensulfonyl chloride, is stirred at room temperature 1 day, reaction completes.Reactant liquor is poured into 1mol/L hydrochloric acid water-soluble In liquid (20ml), add dichloromethane (20ml), point liquid, organic faciess are washed with 1mol/L hydrochloric acid (20ml), then use saturation Na2CO3 (500ml*2) wash, Na2SO4It is dried, filters, be spin-dried for, obtain yellow oil, silica gel column chromatography purification obtains high white of purity Color solid 1, yield 50%, purity 99.5%
Example IV:
Compound 354g 2 is dissolved in 4L dichloromethane, is then added thereto to 120g triethylamine, to it under stirring In to be slowly added dropwise into 165g chlorotriethyl silane be TESCl.After 1h, add water quenching to go out in reactant liquor, then divide liquid, Suo Youyou Machine phase is concentrated to dryness after being dried and obtains 3b.
375g 3b is dissolved in 600mLDMF, adds 270g triazole sodium salt compound 4 and 1,3- diformazan in reactant liquor Base -3,4,5,6- tetrahydrochysene -2 (1H) pyrimidones are DMPU, are heated to 100-110 DEG C and stir 24 hours.Add water (1.5L) be quenched, use Dichloromethane (1000ml*2) extracts, and dichloromethane saturated aqueous common salt (200mL) washed once, Na2SO4It is dried, concentrate, Obtain yellow oil, silica gel column chromatography purification obtains faint yellow solid 5b, yield 55%, purity 97%.
Take 210g 5a to be added in 1500mL dichloromethane, add 60g triethylamine, 1.2g DMAP.0℃ It is dividedly in some parts 120g paratoluensulfonyl chloride, be stirred at room temperature 1 day, reaction completes.Reactant liquor is poured in 1mol/L aqueous hydrochloric acid solution (2000ml), add dichloromethane (1000ml), point liquid, organic faciess are washed with 1mol/L hydrochloric acid (1000ml), then use saturation Na2CO3(500ml*2) wash, Na2SO4It is dried, filter, be spin-dried for, obtain yellow oil, silica gel column chromatography purification obtains purity High white solid 1, yield 53%, purity 98.8%.

Claims (5)

1. the preparation method of the compound 1 of the intermediate preparing posaconazole showing as formula 1 it is characterised in that as formula 5 is shown, with changing Compound 2 is raw material, obtains compound 3 with trialkyl silyl protection hydroxyl first, then reacts with the sodium salt 4 of triazole again, obtain To compound 5, then desiliconization ether carry out p-toluenesulfonyl protection and obtain chemical combination in the presence of paratoluensulfonyl chloride and alkali Thing 1,
In reaction equation, R can be trimethyl silicane or triethyl group silicon or t-Butyldimethylsilyl, and alkali used is potassium carbonate Or sodium carbonate or sodium bicarbonate or triethylamine or pyridine or imidazoles.
2. the preparation method of the compound 1 of the intermediate preparing posaconazole showing as formula 1 according to claim 1, its It is characterised by that preparing formula 6 such as shows, that is,:It is DMF or dichloromethane that compound 2 is dissolved in N,N-dimethylformamide
In alkane, then it is added thereto to alkali and trialkyl silicon chloride RX, reaction obtains compound 3, compound 3 is dissolved in N, N- bis- In methylformamide, in reactant liquor, then add the triazole sodium salt compound 4 of 3-5 times of mole and 1-1.5 mole DMPU, is heated to 80-140 DEG C and is reacted, and is quenched and reacts molten for compound 5 through organic faciess are obtained by extraction after the completion of reaction Liquid, purified after obtain the compound 5 of faint yellow solid, compound 5 is added in dichloromethane, adds triethylamine and 4- bis- Methylamino pyridine, is then dividedly in some parts the paratoluensulfonyl chloride of 1-1.5 mole at 0 DEG C, and reaction is stirred at room temperature, and reaction completes Afterwards, obtain yellow oil after extraction, acid-alkali washing, drying, filtration, dried, then after column chromatography or recrystallization Obtain the compound 1 of white solid.
3. the preparation method of the compound 1 of the intermediate preparing posaconazole showing as formula 1 according to claim 1, its It is characterised by:Compound 2 is dissolved in dichloromethane, is then added thereto to imidazoles, be slowly added dropwise thereto under stirring into Chlorotriethyl silane is reacted, and reaction is then quenched, and the organic faciess obtaining after point liquid obtain chemical combination after drying concentrates again Thing 3b, compound 3b is dissolved in DMF, addition triazole sodium salt compound 4 and 1,3- dimethyl -3 in reactant liquor, and 4,5,6- Tetrahydrochysene -2 (1H) pyrimidone, is heated to 100-110 DEG C of reaction, reaction is then quenched, and through extraction, washing, is dried and concentration Obtain yellow oil, then obtain faint yellow solid 5b through column chromatography purification, 5a is added in dichloromethane, add three second Amine and DMAP, 0 DEG C is dividedly in some parts paratoluensulfonyl chloride, pours reactant liquor into aqueous hydrochloric acid solution after the completion of reaction In, add dichloromethane, organic faciess are washed, are dried, filtering after processing by point liquid, be spin-dried for process after obtain yellow oil, Purified process obtains target compound 1 again.
4. the preparation method of the compound 1 of the intermediate preparing posaconazole showing as formula 1 according to claim 1, its It is characterised by:Compound 2 is dissolved in DMF, is then added thereto to pyridine, delays thereto under stirring Slowly it is added dropwise to tert-butyl chloro-silicane, reaction after reaction, is quenched, then divide liquid, organic faciess are concentrated to give compound after being dried 3b, compound 3b is dissolved in DMF, adds triazole sodium salt compound 4 and DMPU, be heated to 100-110 DEG C in reactant liquor It is quenched after stirring reaction, through extraction, washing, be dried and obtain yellow oil after concentrating, more purified obtain faint yellow solid 5b, compound 5a is added in dichloromethane, adds potassium carbonate, DMAP, 0 DEG C is dividedly in some parts tolysulfonyl Chlorine, is stirred at room temperature reaction, after the completion of reaction pours reactant liquor in aqueous hydrochloric acid solution into, adds dichloromethane, then divides liquid, has Machine is mutually scrubbed, dry, be filtrated to get yellow oil, and silica gel column chromatography purification obtains the compound 1 of white solid.
5. the preparation method of the compound 1 of the intermediate preparing posaconazole showing as formula 1 according to claim 1, its It is characterised by:Compound 2 is dissolved in dichloromethane, then thereto plus triethylamine, be slowly added dropwise thereto under stirring into Chlorotriethyl silane, is quenched reaction after fully reacting, and point liquid is processed, organic faciess are concentrated to give compound 3b, by chemical combination after being dried Thing 3b is dissolved in DMF, adds triazole sodium salt compound 4 and 1,3- dimethyl -3,4,5,6- tetrahydrochysenes -2 (1H) in reactant liquor Pyrimidone, is quenched after being heated to 100-110 DEG C of stirring reaction, through extracting, washed once, be dried and concentration obtain yellow oil Shape thing, the more purified compound 5b obtaining faint yellow solid, compound 5a are added in dichloromethane, add triethylamine And DMAP, 0 DEG C is dividedly in some parts paratoluensulfonyl chloride, and room temperature pours reactant liquor into hydrochloric acid water after the completion of fully reacting In solution, add dichloromethane, organic faciess washing after point liquid, be dried, filter after obtain yellow oil, more purified obtain The compound 1 of white solid.
CN201610771038.8A 2016-08-30 2016-08-30 Preparation method for preparing posaconazole midbody Pending CN106397417A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610771038.8A CN106397417A (en) 2016-08-30 2016-08-30 Preparation method for preparing posaconazole midbody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610771038.8A CN106397417A (en) 2016-08-30 2016-08-30 Preparation method for preparing posaconazole midbody

Publications (1)

Publication Number Publication Date
CN106397417A true CN106397417A (en) 2017-02-15

Family

ID=58002189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610771038.8A Pending CN106397417A (en) 2016-08-30 2016-08-30 Preparation method for preparing posaconazole midbody

Country Status (1)

Country Link
CN (1) CN106397417A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114920686A (en) * 2022-05-20 2022-08-19 山东农业大学 Synthesis method of 5- (benzenesulfonyl) -N-piperidin-4-yl-2- (trifluoromethyl) benzenesulfonamide hydrochloride

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1073944A (en) * 1991-10-30 1993-07-07 先灵公司 Tri-substituted tetrahydrofuran antifungals
WO2009141837A2 (en) * 2008-05-21 2009-11-26 Ind-Swift Laboratories Limited Process for preparing posaconazole and intermediates thereof
CN102892763A (en) * 2010-05-19 2013-01-23 桑多斯股份公司 Purification of posaconazole and posaconazole intermediates
CN102906087A (en) * 2010-05-19 2013-01-30 桑多斯股份公司 Process for the preparation of chiral triazolones
WO2015059716A2 (en) * 2013-10-22 2015-04-30 Msn Laboratories Private Limited Improved process for the preparation of ((3s,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methyl-4-methylbenzenesulfonate
CN105440022A (en) * 2015-12-31 2016-03-30 重庆威鹏药业有限公司 Preparation method of posaconazole main ring

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1073944A (en) * 1991-10-30 1993-07-07 先灵公司 Tri-substituted tetrahydrofuran antifungals
WO2009141837A2 (en) * 2008-05-21 2009-11-26 Ind-Swift Laboratories Limited Process for preparing posaconazole and intermediates thereof
CN102892763A (en) * 2010-05-19 2013-01-23 桑多斯股份公司 Purification of posaconazole and posaconazole intermediates
CN102906087A (en) * 2010-05-19 2013-01-30 桑多斯股份公司 Process for the preparation of chiral triazolones
WO2015059716A2 (en) * 2013-10-22 2015-04-30 Msn Laboratories Private Limited Improved process for the preparation of ((3s,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methyl-4-methylbenzenesulfonate
CN105440022A (en) * 2015-12-31 2016-03-30 重庆威鹏药业有限公司 Preparation method of posaconazole main ring

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEMENEZ, P ET AL.: "Sequential Homoaldolization - Cuprate Rearrangement In A Stereoselective Synthesis Of Stannyl Dienes - Application To The Synthesis Of The Western C10-C15 Subunit Of ±-Tylosin Aglycon", 《JOURNAL OF ORGANIC CHEMISTRY》 *
YODA,H,ET AL.: "Diastereoselective Reactions Of Grignard-Reagents With Chiral Amino Lactols Derived From L-Aspartic Acid", 《TETRAHEDRON-ASYMMETRY》 *
黄培强等: "《有机合成》", 30 June 2004, 高等教育出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114920686A (en) * 2022-05-20 2022-08-19 山东农业大学 Synthesis method of 5- (benzenesulfonyl) -N-piperidin-4-yl-2- (trifluoromethyl) benzenesulfonamide hydrochloride
CN114920686B (en) * 2022-05-20 2023-11-24 山东农业大学 Synthesis method of 5- (benzenesulfonyl) -N-piperidin-4-yl-2- (trifluoromethyl) benzenesulfonamide hydrochloride

Similar Documents

Publication Publication Date Title
US7705159B2 (en) Process for the preparation of letrozole
US9303039B2 (en) Methods useful in the synthesis of halichondrin B analogs
MX2012013334A (en) Process for the preparation of chiral triazolones.
CN104892537B (en) The synthetic method of Ezetimibe intermediate and Ezetimibe
US20110201809A1 (en) Process for Preparing Entecavir and its Intermediates
CN110483549B (en) Preparation method of nitroimidazole pyran antituberculosis drug
CN106397417A (en) Preparation method for preparing posaconazole midbody
US20130012714A1 (en) Novel solvate of dexlansoprazole
CN109415383A (en) Prepare the method and its intermediate of eribulin
CN111943937A (en) Synthesis method of triphenyl candesartan
CN111170893A (en) Lefamulin intermediate compound and application thereof in preparation of Lefamulin
TWI445711B (en) Improved method for preparation of adefovir dipivoxil
US20090221837A1 (en) Process for the Preparation of Pure Anastrozole
CN104530112B (en) The preparation method of everolimus intermediate and its ethylization impurity
Hoppe et al. Enantiomerically pure 2-(carbamoyloxy) oxiranes and their utility in the synthesis of D-and L-3, 6-dideoxy-3-C-methylhexofuranosides via the homoaldol reaction
WO2009017288A1 (en) Process for preparation of disodium stilbenedisulfonates
CN108707080B (en) Environment-friendly synthesis method of linezolid and intermediate thereof
CN108586280B (en) Method for synthesizing N' - [ (2S,3S) -2- (benzyloxy) pentan-3-yl ] formylhydrazine
KR20180050471A (en) A method for preparation of (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrocholoride
CN113195454A (en) Preparation method of amide-like derivative and intermediate thereof
CN103613576A (en) Novel macrocyclic cyclic sulfate, and preparation method and application thereof
US20030149284A1 (en) Method of synthesizing a paclitaxel derivative
CN105985296B (en) It is a kind of can be with the process for refining of industrialized lesinurad intermediates 1- naphthalene triazolinthiones
US9643958B2 (en) Deprotection method for protected hydroxyl group
US9260401B2 (en) Method for preparing cabazitaxel from 10-deacetylbaccatin III in high yield, and novel intermediate therefor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170215